CN Mobile Logo


Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

The efficacy of ponatinib in patients with newly diagnosed CML compared with imatinib remains to be established, as a randomized phase III trial was terminated early due to concerns regarding arterial occlusive events with ponatinib.

A rapid reduction in BCR-ABL transcript levels and the halving time of those levels are predictive of better outcomes in patients with chronic myeloid leukemia.

Patients with CML who are treated with dasatinib commonly experience lymphocytosis, and the condition is associated with higher response rates and increased survival in patients who are refractory or intolerant of imatinib.

Elevated levels of TGF-α and IL-6 in newly diagnosed chronic-phase chronic myeloid leukemia patients were predictive of failure to achieve molecular response.

A study found an increased incidence of non-Hodgkin lymphoma, but no other secondary malignancies, in chronic myeloid leukemia patients treated with imatinib.

Patients with chronic phase CML and pre-existing mild to moderate liver and/or renal dysfunction can be safely treated with frontline nilotinib or dasatinib, according to a new study.

A new personalized DNA-based assay can detect very low levels of persistent disease in chronic myeloid leukemia patients thought to be in deep remission.


Subscribe to Chronic Myeloid Leukemia on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.